<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04865380</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-1983</org_study_id>
    <nct_id>NCT04865380</nct_id>
  </id_info>
  <brief_title>Does Tranexamic Acid Improve Visualization During Arthroscopic Rotator Cuff Repair</brief_title>
  <official_title>Does Tranexamic Acid Improve Visualization During Arthroscopic Rotator Cuff Repair: A Double Blinded, Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial examines whether intravenous preoperative administration of tranexamic&#xD;
      acid (TXA) before arthroscopic rotator cuff repair (ARCR) can improve arthroscopic&#xD;
      visualization during the procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Surgeons are blinded to group allocation and all treatment is administered by the anesthesia care provider. Patients will not be informed of their allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Arthroscopic Visualization Score</measure>
    <time_frame>Surgeon will complete the visualization score immediately after the surgery is completed.</time_frame>
    <description>A visualization score from 1 to 6 assessed by the surgeon.&#xD;
- Perfect visualization&#xD;
- Mild difficulty that could easily be worked around&#xD;
- Moderate difficulty that required modifications to the surgical plan&#xD;
- Significant difficulty that added more than 10 minutes to the case&#xD;
- Major difficulty that added more than 20 minutes to the case&#xD;
- Difficulty that forced the stoppage of the case</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Rotator Cuff Tears</condition>
  <condition>Rotator Cuff Injuries</condition>
  <condition>Subacromial Impingement</condition>
  <condition>Subacromial Impingement Syndrome</condition>
  <arm_group>
    <arm_group_label>No Tranexamic Acid</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The anesthesiologist will not administer Tranexamic Acid at any point.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1g of Tranexamic Acid will be administered intravenously prior to the start of the operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid 100 MG/ML</intervention_name>
    <description>1g IV x 1 dose of Tranexamic Acid administered preoperatively.</description>
    <arm_group_label>Intravenous Tranexamic Acid</arm_group_label>
    <other_name>Sandoz Tranexamic Acid Injection BP 100mg/mL, DIN 02246365</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-100&#xD;
&#xD;
          -  Male and Female&#xD;
&#xD;
          -  Patient able to read and understand consent form&#xD;
&#xD;
          -  Non-traumatic, simple small or medium sized rotator cuff tear as defined by&#xD;
             pre-operative MRI&#xD;
&#xD;
          -  Booked to operating room for elective rotator cuff repair&#xD;
&#xD;
          -  Beach chair positioning&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal to participate&#xD;
&#xD;
          -  Massive rotator cuff tear&#xD;
&#xD;
          -  Acute traumatic rotator cuff tear&#xD;
&#xD;
          -  Known coagulopathy&#xD;
&#xD;
          -  Patients with a history or risk of thromboembolism&#xD;
&#xD;
          -  Known hypersensitivity to tranexamic acid&#xD;
&#xD;
          -  Patient unable to be off anti-coagulant medication for long enough to counter effects&#xD;
&#xD;
          -  Patient has a clinic systolic blood pressure &gt; 150mmHg&#xD;
&#xD;
          -  Lateral positioning&#xD;
&#xD;
          -  Requirement or insistence by patient or anesthesiologist on regional block&#xD;
&#xD;
          -  Patients who have smoked nicotine products within the last year&#xD;
&#xD;
          -  The presence of other inflammatory conditions (calcific tendonitis, rheumatoid&#xD;
             arthritis, etc.)&#xD;
&#xD;
          -  The presence of active thromboembolic disease, such as deep vein thrombosis, pulmonary&#xD;
             embolism, and cerebral thrombosis&#xD;
&#xD;
          -  Patient has a seizure disorder&#xD;
&#xD;
          -  Patients on medications identified as having drug-drug interactions (hormonal&#xD;
             contraceptive, hydrochlorothiazide, desmopressin, sulbactam-ampicilllin,&#xD;
             carbazochrome, ranitidine, or nitroglycerine&#xD;
&#xD;
          -  Patient is pregnant&#xD;
&#xD;
          -  Patients with history of subarachnoid hemorrhage&#xD;
&#xD;
          -  Patients with renal insufficiency&#xD;
&#xD;
          -  Patients with acquired disturbances of color vision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Reed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeremy Reed, MD</last_name>
    <phone>3065664660</phone>
    <email>jreed@usask.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael W Thatcher, Bsc</last_name>
    <phone>3067379541</phone>
    <email>michael.thatcher@usask.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dash &amp; Reed Sports Medicine</name>
      <address>
        <city>White City</city>
        <state>Saskatchewan</state>
        <zip>S4L 5B1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Reed, MD</last_name>
      <phone>3065664660</phone>
      <email>jreed@usask.ca</email>
    </contact>
    <investigator>
      <last_name>Jeremy Reed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Thatcher, Bsc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Jeremy Reed</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shoulder Impingement Syndrome</mesh_term>
    <mesh_term>Rotator Cuff Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

